The role and target potential of protein tyrosine phosphatases in cancer

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Current Oncology Reports

• Publication date

  2008-03-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/S11912-008-0019-6PMID 18377824
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• References Subscriptions Permissions Email Alerts TCR Signaling Thresholds Regulating T Cell Development and Activation Are Dependent

  2013cited by this paper
• Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.

  2007cited by this paper
• MAPK phosphatases — regulating the immune response

  2007cited by this paper
• HER-2/neu raises SHP-2, stops IFN-gamma anti-proliferation in bladder cancer.

  2007cited by this paper
• CDC25 phosphatases in cancer cells: key players? Good targets?

  2007cited by this paper
• Protein tyrosine phosphatase function: the substrate perspective.

  2007cited by this paper
• Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability.

  2007cited by this paper
• Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T

  2007cited by this paper
• Normal TCR Signal Transduction in Mice That Lack Catalytically Active PTPN3 Protein Tyrosine Phosphatase1

  2007cited by this paper
• PRL-3: A Metastasis-Associated Phosphatase in Search of a Function

  2007cited by this paper
• Structurally Unique Inhibitors of Human Mitogen-Activated Protein Kinase Phosphatase-1 Identified in a Pyrrole Carboxamide Library

  2007cited by this paper
• Cdc25 phosphatases: structure, specificity, and mechanism.

  2007cited by this paper
• Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases

  2007cited by this paper
• Cytokine-Based Therapy and Biochemotherapy for Advanced Melanoma

  2006cited by this paper
• Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors.

  2006cited by this paper
• MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock

  2006cited by this paper
• Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance.

  2006cited by this paper
• Activation, coactivation, and costimulation of resting human natural killer cells

  2006cited by this paper
• Biflavonoids inhibited phosphatase of regenerating liver-3 (PRL-3)

  2006cited by this paper
• Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock

  2006cited by this paper
• PM-20, a novel inhibitor of Cdc25A, induces extracellular signal–regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo

  2006cited by this paper
• Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.

  2006cited by this paper
• Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer

  2006cited by this paper
• Diverse physiological functions for dual-specificity MAP kinase phosphatases

  2006cited by this paper
• Targeting Tyrosine Kinases in Cancer: The Second Wave

  2006cited by this paper
• Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis.

  2006cited by this paper
• Protein tyrosine phosphatases: from genes, to function, to disease

  2006cited by this paper
• Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors.

  2006cited by this paper
• PRL-3 Phosphatase Is Implicated in Ovarian Cancer Growth

  2005cited by this paper
• Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases

  2005cited by this paper
• Review: Milstein Award Lecture: Interferons and Cancer: Where from Here?

  2005cited by this paper
• Sodium Stibogluconate Interacts with IL-2 in Anti-Renca Tumor Action via a T Cell-Dependent Mechanism in Connection with Induction of Tumor-Infiltrating Macrophages1

  2005cited by this paper
• Abnormal Th1 Cell Differentiation and IFN-γ Production in T Lymphocytes from Motheaten Viable Mice Mutant for Src Homology 2 Domain-Containing Protein Tyrosine Phosphatase-11

  2005cited by this paper
• Normal Cell Cycle and Checkpoint Responses in Mice and Cells Lacking Cdc25B and Cdc25C Protein Phosphatases

  2005cited by this paper
• PRL phosphatases as potential molecular targets in cancer

  2005cited by this paper
• Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia.

  2005cited by this paper
• Germ-line and somatic PTPN11 mutations in human disease.

  2005cited by this paper
• The biology and clinical relevance of the PTEN tumor suppressor pathway.

  2004cited by this paper
• The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer

  2004cited by this paper
• Inhibition of MKP-1 expression potentiates JNK related apoptosis in renal cancer cells.

  2004cited by this paper
• Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers

  2004cited by this paper
• Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.

  2004cited by this paper
• PEST Domain-Enriched Tyrosine Phosphatase (PEP) Regulation of Effector/Memory T Cells

  2004influential reference
• Expression of PRL-3 Phosphatase in Human Gastric Carcinomas: Close Correlation with Invasion and Metastasis

  2004cited by this paper
• Mouse model of Noonan syndrome reveals cell type– and gene dosage–dependent effects of Ptpn11 mutation

  2004cited by this paper
• High Expression of PRL-3 Promotes Cancer Cell Motility and Liver Metastasis in Human Colorectal Cancer

  2004cited by this paper
• The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

  2003cited by this paper
• Identification of a gene expression signature associated with pediatric AML prognosis.

  2003cited by this paper
• PRL-3 and PRL-1 promote cell migration, invasion, and metastasis.

  2003cited by this paper
• Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells.

  2003influential reference
• PRL-3 expression in metastatic cancers.

  2003cited by this paper
• Enhanced cell cycle progression and down regulation of p21(Cip1/Waf1) by PRL tyrosine phosphatases.

  2003cited by this paper
• Profiling of Hodgkin’s Lymphoma Cell Line L1236 and Germinal Center B Cells: Identification of Hodgkin’s Lymphoma-specific Genes

  2003cited by this paper
• Erratum to: Profiling of Hodgkin’s Lymphoma Cell Line L1236 and Germinal Center B Cells: Identification of Hodgkin’s Lymphoma-specific Genes

  2003cited by this paper
• Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer.

  2003cited by this paper
• Analysis of stromal-epithelial interactions in prostate cancer identifies PTPCAAX2 as a potential oncogene.

  2002cited by this paper
• Pentamidine is an inhibitor of PRL phosphatases with anticancer activity.

  2002cited by this paper
• PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.

  2002cited by this paper
• Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray.

  2002cited by this paper
• The Tyrosine Phosphatase PRL-1 Localizes to the Endoplasmic Reticulum and the Mitotic Spindle and Is Required for Normal Mitosis*

  2002cited by this paper
• Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development.

  2002cited by this paper
• How do inhibitory phosphatases work?

  2002cited by this paper
• Anticancer Activity of Sodium Stibogluconate in Synergy with IFNs1

  2002cited by this paper
• Expression of mitogen‐activated protein kinase phosphatase‐1 (MKP‐1) in primary human ovarian carcinoma

  2002cited by this paper
• Sodium Stibogluconate Is a Potent Inhibitor of Protein Tyrosine Phosphatases and Augments Cytokine Responses in Hemopoietic Cell Lines1

  2001cited by this paper
• A Phosphatase Associated with Metastasis of Colorectal Cancer

  2001cited by this paper
• Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome

  2001cited by this paper
• Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases.

  2001cited by this paper
• Cytoskeletal protein tyrosine phosphatase PTPH1 reduces T cell antigen receptor signaling

  2000cited by this paper
• The tyrosine phosphatase SHP-1 influences thymocyte selection by setting TCR signaling thresholds.

  1999cited by this paper
• Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice

  1999cited by this paper
• Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp.

  1999cited by this paper
• Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis

  1999cited by this paper
• Mitogen-activated protein kinases and apoptosis in PIN

  1998cited by this paper
• The Shp-2 Tyrosine Phosphatase Has Opposite Effects in Mediating the Activation of Extracellular Signal-regulated and c-Jun NH2-terminal Mitogen-activated Protein Kinases*

  1998cited by this paper
• Signaling by the Cytokine Receptor Superfamily a

  1998cited by this paper
• Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1.

  1998cited by this paper
• Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells.

  1998cited by this paper
• Biased Suppression of Hematopoiesis and Multiple Developmental Defects in Chimeric Mice Containing Shp-2 Mutant Cells

  1998cited by this paper
• Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp‐2

  1997cited by this paper
• Macrophages from motheaten and viable motheaten mutant mice show increased proliferative responses to GM-CSF: detection of potential HCP substrates in GM-CSF signal transduction.

  1997cited by this paper
• Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis.

  1997cited by this paper
• P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase.

  1997cited by this paper
• Abnormal development and differentiation of macrophages and dendritic cells in viable motheaten mutant mice deficient in haematopoietic cell phosphatase

  1997cited by this paper
• Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency.

  1997cited by this paper
• Increased G-CSF responsiveness of bone marrow cells from hematopoietic cell phosphatase deficient viable motheaten mice.

  1997cited by this paper
• Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1

  1996cited by this paper
• Signaling capacity of the T cell antigen receptor is negatively regulated by the PTP1C tyrosine phosphatase

  1996cited by this paper
• Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases.

  1996cited by this paper
• Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor.

  1996cited by this paper
• Mammalian SH2-containing protein tyrosine phosphatases.

  1996cited by this paper
• Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals.

  1995cited by this paper
• CDC25 phosphatases as potential human oncogenes.

  1995cited by this paper
• Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1

  1995cited by this paper
• PRL-1, a unique nuclear protein tyrosine phosphatase, affects cell growth

  1994cited by this paper
• Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene.

  1993cited by this paper
• Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13

  1992cited by this paper
• Characterization of hematopoietic intracellular protein tyrosine phosphatases: description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences

  1992cited by this paper
• Footprinting studies on the sequence‐selective binding of pentamidine to DNA

  1990cited by this paper
• Hematologic abnormalities of the immunodeficient mouse mutant, viable motheaten (mev).

  1989cited by this paper

• Phosphatases in tumor cell immune escape: a perspective based on the camouflage, coercion, cytoprotection.

  2026cites this paper
• Setting sail: Maneuvering SHP2 activity and its effects in cancer.

  2023cites this paper
• Role of Protein Tyrosine Phosphatase in Regulation of Cell Signaling Cascades Affecting Tumor Cell Growth: A Future Perspective as Anti- Cancer Drug Target.

  2021cites this paper
• Bioinformatics Analysis of the Molecular Mechanism and Potential Treatment Target of Ankylosing Spondylitis

  2021cites this paper
• EFFECTS OF DETOXIFICATION OF Mucuna pruriens ON THE FEED INTAKE, BEHAVIOR, ORGAN WEIGHTS, BLOOD CELL COUNTS AND METABOLITES OF RATS

  2019cites this paper
• Loss of Tyrosine Phosphatase Delta Promotes Gastric Cancer Progression via Signal Transducer and Activator of Transcription 3 Pathways

  2019cites this paper
• The VE-PTP Inhibitor AKB-9778 Improves Antitumor Activity and Diminishes the Toxicity of Interleukin 2 (IL-2) Administration

  2019cites this paper
• Inhibition of PP 2 A by hesperetin contributes to Akt and ERK 1 / 2 activation in primary cortical neurons

  2018cites this paper
• Inhibition of PP2A by hesperetin may contribute to Akt and ERK1/2 activation status in cortical neurons.

  2018cites this paper
• Synthesis, bioactivity, 3D-QSAR studies of novel dibenzofuran derivatives as PTP-MEG2 inhibitors

  2017cites this paper
• Protein Tyrosine Phosphatase-Prospective Target against Cancer: A Mini Review

  2017cites this paper
• Régulation de l'agressivité tumorale mammaire par la protéine tyrosine phosphatase PTPL1/PTPN13

  2016cites this paper
• Some non-conventional biomolecular targets for diamidines. A short survey.

  2014cites this paper
• Oxidative stress impairs multiple regulatory events to drive persistent cytokine-stimulated STAT3 phosphorylation.

  2014cites this paper
• Targeting Clinically Viable Protein Tyrosine Phosphatases with Rationally Designed, Small Molecule Inhibitors and Artificially Induced Protein-Membrane Anchors

  2014cites this paper
• Naturally-occurring dimers of flavonoids as anticarcinogens.

  2013cites this paper
• Identification of the Structural Features that Mediate Binding Specificity in the Recognition of STAT Proteins by Dual-Specificity Phosphatases

  2012cites this paper
• Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer

  2012cites this paper
• Yersinia pestis and approaches to targeting its outer protein H protein-tyrosine phosphatase (YopH).

  2012cites this paper
• Analysis of BMP4 and BMP7 signaling in breast cancer cells unveils time-dependent transcription patterns and highlights a common synexpression group of genes

  2011cites this paper
• Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects

  2011cites this paper
• Using small molecules to target protein phosphatases.

  2011cites this paper
• Decreased Diacylglycerol Metabolism Enhances ERK Activation and Augments CD8+ T Cell Functional Responses*

  2010cites this paper
• Novel SHP-1 Inhibitors Tyrosine Phosphatase Inhibitor-1 and Analogs with Preclinical Anti-Tumor Activities as Tolerated Oral Agents

  2010cites this paper
• Pharmacological Targeting of the Mitochondrial Phosphatase PTPMT1

  2010cites this paper
• Tolerated Oral Agents Preclinical Anti-Tumor Activities as Phosphatase Inhibitor-1 and Analogs with Novel SHP-1 Inhibitors Tyrosine

  2010cites this paper
• The therapeutic potential of phosphatase inhibitors.

  2009cites this paper
• Bypass of hexavalent chromium-induced growth arrest by a protein tyrosine phosphatase inhibitor: enhanced survival and mutagenesis.

  2009cites this paper
• Dual-specificity phosphatases: critical regulators with diverse cellular targets.

  2009cites this paper
• Docking Study of Biflavonoids, Allosteric Inhibitors of Protein Tyrosine Phosphatase 1B

  2008cites this paper